Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-02 · 399 (4) · 6151-6160
DOI: 10.1007/s00210-025-04726-3 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 18.11.2025. Verfasst von Alaa Abdrabou Abouelmagd und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, South Valley University, Qena, Egypt. Alaa.AbdRabbo@med.svu.edu.eg. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: South Valley University.
Abstract (Originalsprache)
Lorundrostat, a novel selective aldosterone synthase inhibitor, has emerged as a potential treatment for uncontrolled hypertension. However, a comprehensive summary of its efficacy and safety profile is currently lacking. This meta-analysis aims to synthesize evidence from published randomized controlled trials (RCTs) to evaluate the clinical benefits and risks of lorundrostat in this patient population. Following the PRISMA guidelines, a systematic search was conducted on PubMed, Scopus, and Web of Science for RCTs comparing lorundrostat with placebo. The primary outcomes were changes from baseline in systolic and diastolic blood pressure. Data were pooled using a random-effects model to calculate mean differences (MD) for continuous outcomes and risk ratios (RR) for dichotomous outcomes, with corresponding 95% confidence intervals (CIs). Three RCTs comprising 1568 patients were included. Compared to placebo, lorundrostat significantly reduced both 24-h systolic blood pressure (MD: − 6.65 mmHg; 95% CI: [− 9.95 to − 3.35]) and office systolic blood pressure (MD: − 7.94 mmHg; 95% CI: [− 9.72 to − 6.15]). While the risk of serious adverse events was comparable, lorundrostat was associated with a higher incidence of hyperkalemia (RR: 5.47; 95% CI: [1.55 to 19.36]) and hyponatremia (RR: 1.95; 95% CI: [1.13 to 3.36]). Notably, lorundrostat significantly reduced the risk of adrenal insufficiency (RR: 0.15; 95% CI: [0.03 to 0.91]). Lorundrostat may be an effective agent for lowering blood pressure in patients with uncontrolled hypertension. Its safety profile is acceptable but requires careful monitoring of serum electrolytes and renal function. The reduced risk of adrenal insufficiency highlights its selectivity and potential as a valuable therapeutic option. Further large-scale, long-term studies are needed to confirm its sustained benefits and safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, South Valley University, Qena, Egypt. Alaa.AbdRabbo@med.svu.edu.eg.
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt.
- Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
- Faculty of Medicine, Cairo University, Cairo, Egypt.
- Faculty of Medicine, South Valley University, Qena, Egypt.
Förderung
- South Valley University
Zitieren
APA
Abouelmagd, A. A., Ramadan, S., Sayed, M. S., Saad, O. A., Yassin, M. N., Mostafa, A. M., & Abdelsayed, K. (2026). Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(4), 6151-6160. https://doi.org/10.1007/s00210-025-04726-3
Vancouver
Abouelmagd AA, Ramadan S, Sayed MS, Saad OA, Yassin MN, Mostafa AM, et al. Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(4):6151-6160. doi:10.1007/s00210-025-04726-3
BibTeX
@article{Abouelmagd2026,
author = {Abouelmagd, Alaa Abdrabou and Ramadan, Shrouk and Sayed, Mohamed Saad and Saad, Omar Abdulrahman and Yassin, Mazen Negmeldin and Mostafa, Alaa Mohammed and Abdelsayed, Kerollos},
title = {Efficacy and safety of lorundrostat in uncontrolled hypertension: a meta-analysis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {4},
pages = {6151--6160},
doi = {10.1007/s00210-025-04726-3}
}
EUVIMED